A revolutionary cancer-targeting technology developed by researchers at Immunocore Limited has been described for the first time in the prestigious medical journal, Nature Medicine. The new reagents known as ImmTACs (Immune Mobilising mTCR against Cancer) mobilise T cells to kill cancer cells and overcome immune tolerance to cancer. For more information click on the link below:- [...]
Oxford-based cancer therapeutics company Immunocore and Scottish Health Innovations (SHIL) were the winners at the coveted 2011 Genesis Awards, announced at a special Awards Dinner following the conclusion of Genesis 2011. Harriet Fear, CEO of One Nucleus said that competition was fierce and showed that despite the current economic downturn, there is a wealth of [...]
Immunocore, together with the French pre-clinical imaging company Animascope, has been awarded a European Union Eurostars project award.
The first three patients with melanoma have completed dosing in the IMCgp100 phase I trial in the UK. Enrolment is now open for the second cohort in which patients will be given a higher dose, as planned. This is the first milestone in a dose-finding study in patients with advanced malignant melanoma, designed to establish a tolerability of increasing doses of IMCgp100 When this arm of the study is complete, a second phase is planned to assess the effect of the selected dose on pharmacodynamic markers when given repeatedly to a larger group of patients.
Immunocore announced today that it has received a US$100,000 Grand Challenges Explorations grant from the Bill & Melinda Gates Foundation. The grant will support an innovative global health research project conducted by Dr. Bent Jakobsen, Chief Scientific Officer, titled “curing HIV through elimination of latently infected cells”.
IMCgp100, a targeted therapeutic for the treatment of advanced metastatic melanoma, has entered clinical trials in the UK and USA. IMCgp100 is the first clinical candidate originating from Immunocore’s innovative ImmTAC technology platform and a new treatment could benefit many thousands of patients diagnosed with skin cancer each year.
Immunocore Limited, the Oxford-based pioneer of T cell receptor technology, announces the appointment of Dr Jonathan Knowles to the Board as a non-executive director.
A partnership with a world-leading research group at Cardiff University will refine new drugs to treat cancer, HIV and autoimmune disease.
MediGene AG and three private investors have founded Immunocore Ltd, which will focus on developing the technology platform for monoclonal T-cell receptors.